For Medical Professionals

“Recent data suggest that Ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades.”

Thomas Insel – Director, National Institute of Mental Health

We Partner With You

At Boulder Mind Care we aim to partner with mental healthcare professionals across northern Colorado to provide a new hope for patients through ketamine infusion therapy.  We understand that, although providers are becoming more educated and aware of the benefits ketamine can provide, they may be simply inexperienced or uncomfortable with infusion procedures,  and/or their facilities may not be properly set up to perform them.

As a board-certified anesthesiologist, Dr. Grindle is highly trained and experienced in administering Ketamine intravenously, and monitoring patients during an infusion.   He understands the severity of the mental conditions, and fragile state of some patients.

Dr. Grindle feels strongly that a team-based approach is in the best interest of his ketamine infusion patients; this is one of the reasons it is a requirement for all Boulder Mind Care patients to be under the care and supervision of a Psychiatrist, Therapist, Family Physician, or other mental healthcare professional qualified to diagnose and treat mental illness.

All patients sign a consent form allowing Boulder Mind Care access to information pertaining to their mental healthcare and permission to speak to their provider. Prior to the initial treatment, Dr. Grindle will personally call the patient’s mental health care professional to initiate a dialog about the patient’s condition, and Boulder Mind Care’s intentions to administer Ketamine Infusion therapy.

,

Ketamine Infusions Provide Effective Relief for Severe Chronic Headache

Medical research is revealing more and more applications for ketamine, the old drug being used in new ways. Just as with Treatment Resistant Depression, where ketamine provides relief in 80% of patients, it is also often successful at relieving…
, ,

New Insight Into How Ketamine Works in Depression

Ketamine exerts an initial antidepressant effect by blocking the N-methyl-D-aspartate receptor (NMDAR), and the ketamine metabolite hydroxynorketamine (HNK) may extend the duration of the effect. The findings could lead to the development of…
,

FDA Data Support Ketamine as Depression Therapy

An analysis of data from the FDA Adverse Events Reporting System (FAERS) supported previous findings that ketamine could be an effective treatment for depression, researchers found. more...
,

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis…
,

Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015

There are multifaceted views on the use of ketamine, a potentially addictive substance, to treat mental health problems. The past 15 years have seen growing media coverage of ketamine for medical and other purposes. This study examined the…
,

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

Several studies now provide evidence of ketamine hydrochloride’s ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small…
,

Depression: How effective are antidepressants?

Like psychological approaches, antidepressants are a key part of treating depression. They aim to relieve symptoms and prevent depression from coming back. more...
,

Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders

Major Depressive Disorder (MDD) is a leading cause of disability worldwide. Despite a plethora of established treatments, less than one-third of individuals with MDD achieve stable remission of symptoms. Given limited efficacy and significant…
,

How does ketamine elicit a rapid antidepressant response?

A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-d-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder. Depressed patients…
,

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Newer antidepressants are needed for the many individuals with major depressive disorder (MDD) that do not respond adequately to treatment and because of a delay of weeks before the emergence of therapeutic effects. Recent evidence from clinical…
,

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are…